Cargando…

Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies

BACKGROUND: Hepatitis C virus (HCV) direct-acting antiviral therapy is effective among people receiving opioid substitution therapy (OST), but studies are limited by small numbers of nongenotype 1 (GT1) patients. The aim of this study was to evaluate the treatment completion, adherence, SVR12, and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grebely, Jason, Feld, Jordan J, Wyles, David, Sulkowski, Mark, Ni, Liyun, Llewellyn, Joe, Mir, Heshaam M, Sajed, Nika, Stamm, Luisa M, Hyland, Robert H, McNally, John, Brainard, Diana M, Jacobson, Ira, Zeuzem, Stefan, Bourlière, Marc, Foster, Graham, Afdhal, Nezam, Dore, Gregory J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808802/ https://www.ncbi.nlm.nih.gov/pubmed/29450210 http://dx.doi.org/10.1093/ofid/ofy001

Ejemplares similares

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data
por: Wilder, Julius M., et al.
Publicado: (2015)

Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment
por: Sulkowski, Mark, et al.
Publicado: (2022)

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
por: Lawitz, Eric, et al.
Publicado: (2015)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials
por: Grebely, Jason, et al.
Publicado: (2018)

Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India
por: Sood, Ajit, et al.
Publicado: (2019)

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices
por: Afdhal, N H, et al.
Publicado: (2013)

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection
por: Feld, Jordan J., et al.
Publicado: (2016)

Analysis of Subgroup Differences in the ION-3 Trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C Infection
por: Kowdley, Kris V., et al.
Publicado: (2015)

The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment
por: Gane, Edward J., et al.
Publicado: (2017)

Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?
por: Bourlière, Marc, et al.
Publicado: (2018)

Emerging therapies for the treatment of hepatitis C
por: Lange, Christian M, et al.
Publicado: (2014)

Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016)

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection
por: Rosenthal, Philip, et al.
Publicado: (2019)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation
por: Cardona‐Gonzalez, Maria G., et al.
Publicado: (2018)

Retinopathy and Uveitis Associated with Sofosbuvir Therapy for Chronic Hepatitis C Infection
por: Chin-Loy, Katrina, et al.
Publicado: (2016)

Antineutrophil cytoplasmic antibodies crescentic allograft glomerulonephritis after sofosbuvir therapy
por: Gadde, Shilpa, et al.
Publicado: (2016)

Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference?
por: Sarwar, Shahid, et al.
Publicado: (2017)

Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1
por: Ruane, Peter, et al.
Publicado: (2017)

Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy
por: El-Shabrawi, Mortada HF, et al.
Publicado: (2019)

Correction: Retinopathy and Uveitis Associated with Sofosbuvir Therapy for Chronic Hepatitis C Infection
por: Chin Loy, Katrina, et al.
Publicado: (2016)

Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation
por: Khemichian, Saro, et al.
Publicado: (2015)

Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
por: Tapper, Elliot B., et al.
Publicado: (2016)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
por: Tang, L., et al.
Publicado: (2018)

Bleeding events in lusutrombopag‐treated thrombocytopenic patients
por: Giannini, Edoardo Giovanni, et al.
Publicado: (2021)

The Efficacy and Safety of Sofosbuvir/Ledipasvir Therapy in Patients on Long-term Hemodialysis with Hepatitis C Virus Infection
por: Cavoli, G. Li, et al.
Publicado: (2018)

Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy
por: Ismail, Bahaaeldeen, et al.
Publicado: (2022)

Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia
por: Yousafzai, Mohammad T., et al.
Publicado: (2022)

Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
por: Takehara, Tetsuo, et al.
Publicado: (2018)

Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients
por: Ajlan, A., et al.
Publicado: (2016)

Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance
por: Sasaki, Ritsue, et al.
Publicado: (2019)

Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals
por: Izumi, Namiki, et al.
Publicado: (2018)

Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin
por: Suii, Hirokazu, et al.
Publicado: (2017)

Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study
por: Jamil, Zubia, et al.
Publicado: (2018)

Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China
por: Hu, Chengguang, et al.
Publicado: (2018)

Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy
por: Cusato, Jessica, et al.
Publicado: (2022)

Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature
por: Sato, Ken, et al.
Publicado: (2019)

Hypoxic cell sensitizers: early or late in fractionated therapy?
por: Denekamp, J., et al.
Publicado: (1978)

Cannot write session to /tmp/vufind_sessions/sess_q49413jnmrn2gbuna9vnrgcfne